Beyond FGFR3 inhibitors as biomarker-informed therapies [12], and in the absence of other molecularly informed decisions, the subsequent-line setting will likely utilize chemotherapy in patients who remain fit and without significant neuropathy from EVP. Here, FGFR3 is linked to neuropathy.